Stockscreener 앱 받기
253.42
0.17%
-0.44
시간 외 거래:
253.34
-0.08
-0.03%
전일 마감가:
$253.86
열려 있는:
$255.56
하루 거래량:
365.41K
Relative Volume:
0.50
시가총액:
$16.62B
수익:
$1.01B
순이익/손실:
$581.90M
주가수익비율:
28.56
EPS:
8.8733
순현금흐름:
$50.57M
1주 성능:
+0.66%
1개월 성능:
-2.81%
6개월 성능:
+6.12%
1년 성능:
+51.32%
1일 변동 폭
$252.93
$258.58
1주일 범위
$249.99
$258.86
52주 변동 폭
$160.86
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
253.42 | 16.65B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S 주식(ASND)의 최신 뉴스
ASND|Ascendis Pharma A/S|Price:256.235|Chg%:+2.375 - TradingKey
Ascendis Pharma A/S (ASND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ascendis Pharma A/S (ASND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns - Yahoo Finance
Ascendis Pharma AS (STU:A710) Shiller PE Ratio : (As of Jul. 24, 2026) - GuruFocus
Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $300 - 富途牛牛
Ascendis Pharma (ASND) Could Be 14% Below Fair Value As Growth Hopes Hold - simplywall.st
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup - ChartMill
Ascendis Pharma A/S (ASND) Stock Analysis: Unpacking a 15.68% Potential Upside for Investors - DirectorsTalk Interviews
Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on February 12, 2025. - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ASND5566766 Bond Profile — Key Metrics - TradingView
Price to earnings forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57 - Stock Titan
Price to book forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Ascendis Pharma A/S – DUS:A710 - TradingView
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $306 - Moomoo
BofA raises Ascendis Pharma stock price target on revenue outlook - Investing.com
Ascendis Pharma: Precision in Princeton - New Jersey Business Magazine
Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Giant with 144% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Price to sales forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Enterprise value to EBIT forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia - Yahoo Finance
Enterprise value to revenue forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong - simplywall.st
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to revenue forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Ascendis Pharma : ASND - 24/7 Wall St.
Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says - Moomoo
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $327 - Moomoo
Ascendis Pharma (ASND) Investor Update Summary - Quartr
Ascendis Pharma (ASND) Q3 2025 earnings summary - Quartr
Ascendis Pharma (ASND) Q3 2024 earnings summary - Quartr
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345 - Moomoo
Ascendis Pharma (ASND) Study Update Summary - Quartr
RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $280 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings and Promising Revenue Growth Capture Investor Interest - DirectorsTalk Interviews
ASNDAscendis Pharma A/S Volatility & Greeks - Finviz
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data - simplywall.st
Ascendis Pharma Q2 2025 Earnings Preview - MSN
Ascendis Pharma: Behind The Stock Surge - Seeking Alpha
Ascendis Pharma added to Russell 3000, Russell 1000 and other US indexes - MSN
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia - TipRanks
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results - Stock Titan
Ascendis Pharma A S (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):